ArticleJMIR medical informatics2026
Prediction of Blood Transfusion Need and Dose in Patients With Upper Gastrointestinal Bleeding: Retrospective Multicenter Prediction Model Study.
Article in JMIR medical informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transfusion thresholds in upper gastrointestinal bleeding are debated; hemoglobin cutoffs of 70-80 g/L are widely cited yet inconsistently applied. Common risk scores offer limited individualized guidance and rarely provide calibrated, interpretable predictions for transfusion decisions. Objective: This study aimed to develop and validate a two-stage, clinically constrained gradient-boosting framework (Medically Constrained Gradient Boosting [MCGB]) that predicts transfusion need and estimates transfusion dose with quantified uncertainty and to implement a prototype recommendation system for clinical use. Methods: We analyzed a retrospective multicenter cohort of 849 adults with endoscopically confirmed upper gastrointestinal bleeding admitted to 3 hospitals in Chongqing, China (January 2019 to August 2025). Predictors available before the transfusion decision included demographics, first recorded vital signs, initial laboratory indices, and clinician-adjudicated etiology. Stage 1 used a calibrated classifier with prespecified monotonic constraints and stability-screened, clinically justified interactions. Stage 2 modeled transfusion dose via quantile predictions with conformal adjustment to generate 95% prediction intervals. Performance was assessed using a cross-site hold-out design. Overall, 2 hospitals were used as the development cohort, within which stratified 5-fold cross-validation was performed for model development, hyperparameter tuning, interaction screening, and calibration. The remaining hospital was held out as an independent test cohort for final evaluation. Hospital-wise alternating external testing was further conducted as a supplementary robustness analysis to assess performance stability across institutions. Classification performance was evaluated using discrimination metrics (area under the receiver operating characteristic curve and area under the precision-recall curve), calibration metrics, and decision-curve analysis; regression performance was evaluated using R², mean absolute error, and prediction-interval coverage. A graphical user interface was implemented to enable clinicians to input patient data and obtain calibrated predictions of transfusion probability and corresponding dose recommendations. Results: MCGB achieved strong discrimination and good calibration across subgroups (area under the receiver operating characteristic curve=0.97 and area under the precision-recall curve=0.91). At a reference probability threshold of .50, sensitivity, specificity, and F1-scores were 0.99, 0.87, and 0.85, respectively, providing a representative operating point for comparison. For dose prediction among transfused patients, MCGB achieved R² of 0.95 and mean absolute error 0.04; 95% prediction-interval coverage was 0.94, indicating accurate point estimates with reliable uncertainty quantification. The software prototype further demonstrated feasibility of real-time decision support at the bedside. Conclusions: MCGB provides calibrated, interpretable predictions of transfusion need and individualized dose in upper gastrointestinal bleeding and may support bedside decision-making and blood-bank planning, with a prototype interface demonstrating potential for clinical deployment. External validation in additional settings is warranted to confirm generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.